Coadministration of CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell Acute Lymphoblastic Leukemia: A Single-Arm, Multicenter, Phase II Trial.

Tianyi WangYanjing TangJiaoyang Cai Xinyu Wan Shao-Yan Hu Xiaoxi LuZhiwei XieXiaohong QiaoHui JiangJingbo ShaoFan YangHong RenQing CaoJuan QianJian ZhangKang AnJianmin WangChengjuan LuoHuanhuan LiangYan MiaoYani MaXiang WangLixia DingLili SongHailong HeWenhua ShiPeifang XiaoXiaomin YangJing YangWenjie LiYiping ZhuNingling WangLongjun GuQimin ChenJingyan TangJun J YangCheng ChengWing-Hang LeungJing ChenJun LuBenshang LiChing-Hong Pui

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)

CD19-/CD22-CAR T-cell therapy achieved relatively durable remission in children with relapsed or refractory B-acute lymphoblastic leukemia, including those with isolated or combined extramedullary relapse.

Keyphrases

cell therapy
acute lymphoblastic leukemia
stem cells
allogeneic hematopoietic stem cell transplantation
mesenchymal stem cells
young adults
nk cells
cross sectional
open label
disease activity
randomized controlled trial
double blind
early life
ulcerative colitis
free survival
placebo controlled